Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Dec 06, 2024

BUY
$0.52 - $1.05 $104,972 - $211,964
201,871 New
201,871 $183,000
Q1 2024

May 15, 2024

BUY
$0.52 - $1.05 $29,629 - $59,827
56,979 Added 39.33%
201,871 $183,000
Q4 2023

Feb 14, 2024

BUY
$0.6 - $1.65 $39,546 - $108,753
65,911 Added 83.45%
144,892 $107,000
Q3 2023

Nov 14, 2023

BUY
$1.67 - $3.33 $40,163 - $80,086
24,050 Added 43.78%
78,981 $132,000
Q2 2023

Aug 14, 2023

BUY
$2.83 - $4.94 $25,540 - $44,583
9,025 Added 19.66%
54,931 $155,000
Q3 2022

Nov 14, 2022

BUY
$8.24 - $12.56 $40,005 - $60,978
4,855 Added 11.83%
45,906 $430,000
Q1 2022

May 16, 2022

BUY
$9.94 - $12.65 $240,607 - $306,205
24,206 Added 143.7%
41,051 $499,000
Q4 2021

Feb 14, 2022

BUY
$11.99 - $18.14 $587 - $888
49 Added 0.29%
16,845 $205,000
Q2 2021

Aug 16, 2021

SELL
$12.38 - $29.19 $22,803 - $53,767
-1,842 Reduced 9.88%
16,796 $240,000
Q1 2021

May 17, 2021

SELL
$15.07 - $21.71 $3,059 - $4,407
-203 Reduced 1.08%
18,638 $405,000
Q4 2020

Feb 16, 2021

BUY
$12.72 - $16.16 $54,950 - $69,811
4,320 Added 29.75%
18,841 $285,000
Q2 2020

Aug 14, 2020

SELL
$12.39 - $17.33 $67,946 - $95,037
-5,484 Reduced 27.41%
14,521 $248,000
Q1 2020

May 15, 2020

BUY
$9.12 - $17.78 $8,600 - $16,766
943 Added 4.95%
20,005 $264,000
Q4 2019

Feb 14, 2020

BUY
$16.11 - $25.98 $73,171 - $118,001
4,542 Added 31.28%
19,062 $307,000
Q2 2019

Aug 14, 2019

BUY
$17.68 - $21.57 $13,083 - $15,961
740 Added 5.37%
14,520 $312,000
Q4 2018

Feb 14, 2019

BUY
$12.45 - $23.47 $21,040 - $39,664
1,690 Added 13.98%
13,780 $179,000
Q3 2018

Nov 14, 2018

BUY
$17.57 - $23.95 $23,157 - $31,566
1,318 Added 12.24%
12,090 $290,000
Q2 2018

Aug 14, 2018

SELL
$11.6 - $19.27 $17,910 - $29,752
-1,544 Reduced 12.54%
10,772 $206,000
Q3 2017

Nov 14, 2017

BUY
$12.6 - $16.34 $155,181 - $201,243
12,316
12,316 $169,000

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $257M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.